Phase I clinical trial of oral suberoylanilide hydroxamic acid - SAHA (MSK390) [vorinostat] in patients with advanced solid tumors and hematologic malignancies

Trial Profile

Phase I clinical trial of oral suberoylanilide hydroxamic acid - SAHA (MSK390) [vorinostat] in patients with advanced solid tumors and hematologic malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 29 May 2013

At a glance

  • Drugs Vorinostat (Primary)
  • Indications Bladder cancer; Breast cancer; Follicular lymphoma; Haematological malignancies; Head and neck cancer; Hodgkin's disease; Leukaemia; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 15 Jul 2008 The expected completion date for this trial has been identified as Dec 2005, as reported by ClinicalTrials.gov.
    • 15 Jul 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 04 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top